Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
https://www.fool.co.uk/2023/03/15/is-the-avacta-share-price-dip-a-buying-opportunity/
Absolutely clueless.
but remains optimistic.
Let's all hope she has been informed about Avacta's incredible AVA 6000.
Developing the next generation of cancer therapies
pre|CISION™ technology
Avacta’s proprietary pre|CISION™ technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAPa) which is highly upregulated in the tumour microenvironment of most solid tumours compared with healthy tissues. The pre|CISION™ substrate can be utilised in a drug conjugate linker or to generate FAPa-activated chemotherapy – that are only activated in the tumour.
When added to a chemotherapy, the pre|CISION™ substrate prevents the drug from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this FAPa-activated approach, the systemic exposure to the chemotherapy is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments is improved.
Avacta’s long term focus is on achieving a more durable response for patients through synergy of the innate immune response to pre|CISION™ chemotherapies with the adaptive immune response to Affimer® immunotherapies in the form of co-administered combinations and in novel tumour-microenvironment activated drug conjugates
(TMAC®).
KEY BENEFITS
Avacta’s proprietary pre|CISION™ technology has a number of essential advantages.
Tumour targeting
Fibroblast activation protein alpha (FAPa) is a protease expressed at 10-100-fold above background in many solid tumours, including breast, pancreatic, liver, lung and ovarian tumours. The pre|CISION™ substrate is specifically cleaved by FAPa and not by any other enzyme, providing a targeting mechanism that ensures localised release of chemotherapeutic agents in the tumour.
FAPa activated drugs
When conjugated to a chemotherapy the pre|CISION™ substrate prevents the drug from entering cells, rendering it inactive. Thus, the pre|CISION™ platform can be used to generate FAPa activated forms of many chemotherapies, that are inactive in circulation and activated in the tumour microenvironment. As a result of this targeting, systemic exposure to the active drug is limited, creating the potential for increased and longer-duration dosing.
Tumour microenvironment activated drug conjugates (TMAC®)
Incorporating pre|CISION™ technology in the linker of Affimer-drug conjugates ensures localised, extracellular release of a chemotherapy payload in the tumour microenvironment. This mechanism overcomes the need to target an internalising cancer marker, as with conventional drug conjugates, allowing the Affimer® to be selected to target an immune checkpoint. Thus, the innate immune response to the chemotherapy is supported by the Affimer® immune checkpoint blockade in this novel class of checkpoint targeting tumour microenvironment activated drug conjugates – TMAC®.
Yes, all the talk a,while back about how the SP will rise when the shorts start buying back in.
But what actually happens is the price is deliberately kept down to let their buddies out.
One of the many problems of investing on AIM I suppose.
These guys are obviously very well researched and seem to know exactly what they are talking about.
I've been invested for over three years now, but I'll definitely be selling up first thing tomorrow morning.
Continued -
When we go and look at an oncology project, it’s very different from what it was even two years ago, because it’s the same people who built Lynparza and Tagrisso and the immunoncology products in Astra, are now with us. So our judgment and ability to design studies and do deals is materially different,” he said.
GSK is trying to rebuild its capability in oncology, after the previous management team exited the area in a deal that gave their cancer drugs and pipeline to Novartis in 2015.
But analyst concerns that GSK’s efforts so far have been lacklustre were compounded last month when the company had to withdraw its Blenrep drug from the US market after a negative trial result. Miels said there was the potential for GSK to refile for approval for Blenrep based on other studies that had yet to report results.
He said GSK was not trying to beat the biggest players in oncology. Instead, the company was focusing its oncology business on creating drugs for seriously ill patients who do not respond to other treatments, in a “salvage strategy”.
He pointed to recent positive results that showed that Jemperli, its version of the breakthrough PD-1 drugs, can outperform the megablockbuster in the category, Merck’s Keytruda. He said this showed it could be used by patients who were no longer improving on Keytruda.
“I don’t think our strategy of going head to head and trying to be the next Roche, or trying to be the next Astra?.?.?.?is the way forward for us,” he said.
FT article.
GSK’s chief commercial officer is looking to acquire or partner with biotechs “hiding in plain sight”, as the UK drugmaker focuses on replenishing its drug pipeline.
Luke Miels said the company was hoping to avoid “getting into a bidding war” by identifying under-appreciated targets worth $1bn-$2.5bn, such as its acquisition of Sierra Oncology earlier this year.
After the worst sell-off in biotech stocks since the early 2000s, analysts have been forecasting a boom in mergers and acquisitions next year. Earlier this month, Amgen bought Horizon Therapeutics for $28bn.
Miels said he was now spending far more time than usual on business development — half a day, or a day a week — as he hopes to secure drugs that will be approved in the medium term.
He is working closely with the new chief scientific officer Tony Wood, who took over from Hal Barron in August. Barron, who left to join longevity start-up Altos Labs but remains an adviser to GSK, was criticised by some analysts for focusing on earlier-stage projects.
“Hal did a lot of work on the early stage, which we needed to do, fix the discovery machinery. Tony and I are very focused on: what else do we need now? Right now? And let’s bring it in,” said Miels. “But not just?.?.?.?any old thing.”
Miels, who joined from AstraZeneca in 2017, has hired many business development, marketing, and clinical trial leaders from his former company. Most recently, Chris Sheldon joined from AstraZeneca, after the companies settled a lawsuit that claimed that his move broke a non-compete clause in his Astra contract.
Miels said these hires boosted GSK’s capability, especially in oncology, where AstraZeneca has far outperformed the company.
“When we go and look at an oncology project, it’s very different from what it was
They want EU to do the same.
Italy mandates COVID tests for travelers from China
Beijing has lifted its zero-COVID policies, which included months-long lockdowns.
HONG KONG-CHINA-HEALTH-VIRUS-ECONOMY-TRAVEL
Other countries, including Japan, India and Malaysia have implemented similar measures | Peter Parks/AFP via Getty Images
BY SARAH-TAÏSSIR BENCHARIF
DECEMBER 28, 2022 6:03 PM CET
Share on Facebook
Share on Twitter
Share on Linkedin
Share on WhatsApp
Mail
Italy has ordered mandatory coronavirus tests for all travelers arriving from China, the health minister announced on Wednesday.
Orazio Schillaci said the tests — including antigen swabs and virus sequencing — were essential to ensure the surveillance and identification of any COVID-19 variants and protect the Italian population.
The health minister has already been following the results of swabs carried out on passengers arriving at Malpensa airport from China since December 24, the health ministry said, and recommended the sequencing of all variants.
Out of 212 swabs carried out at Malpensa airport on travelers arriving directly from China on two flights on Boxing Day, 97 were positive for COVID-19, reports La Stampa. Those who tested positive were isolated, with contact tracing initiated.
Schillaci’s announcement on Wednesday comes in the wake of China’s lifting of its zero-COVID policies, which included months-long lockdowns. The country’s U-turn on the strict measures is already leading to its biggest outbreak of COVID-19 infections since the pandemic’s start, with medical staff struggling to cope.
The United States also later said Wednesday it will require anyone arriving by air from China to provide a negative COVID test.
Other countries, including Japan, India and Malaysia have already implemented measures for travelers arriving from China, reports Reuters.
This article was updated to include the United States’ announcement.
MORE FROM ... SARAH-TAÏSSIR BENCHARIF
Next up up big today, just a thought!